Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases.
Szpręgiel I, Bysiek A
Publication record · Explore literaturePublic tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.
References — this paper cites (0)
No references identified in the available metadata. This does not establish that none exist.
Cited by — these papers cite this paper (5)
- Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development 2026-07-03 · Expand citations
- Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats 2026-07-01 · Expand citations
- Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamine 2026-05-01 · Expand citations
- Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms 2026-05-01 · Expand citations
- Classic psychedelics in obsessive-compulsive disorder: a circuit-based framework 2026-03-31 · Expand citations